Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
Doctor of Philosophy (Ph.D.)
Bachelor’s Degree
2020
Venture investment and newco creation across US and Asia, focusing on therapeutics
2018 - 2020
2018 - 2020
Supported Senior Biotech Analyst, Andrew Fein, in conducting fundamental analysis, forming investment thesis and authoring research reports with focus on SMid-Cap biotech companies: -- Initiated coverage: KROS, ARVN, ZNTL, CNST, DCPH, BPMC, RUBY, APRE, MEIP, UMRX, SNSS -- Additional coverage (30+ companies) include: SGEN, VRTX, BCRX, KDMN, EPZM, SYRS etc.
2017 - 2018
2017 - 2018
-- Assisted in the construction of venture capital investment portfolio of $100M, which is part of Varian’s long-term strategy to transform from a radiation oncology company to an integrated multi-modality cancer company; -- Performed market segment analysis for investment and partnership opportunities and reported to company executives on recommendations to pursue, with focus on cancer immunotherapies and biomarkers; -- Facilitated equity investment in Omniox ($90M Series D) by leading external and internal meetings (across business development team, translational oncology team, medical affairs team and legal team) and proposing partnership strategies; -- Performed equity investment transaction due diligence including clinical trial data analysis, preclinical data and patent analysis, competitive landscape analysis, financial modeling and valuation; -- Constructed and managed a comprehensive interactive cancer clinical trial database.
2011 - 2017
2011 - 2017
Molecular cellular research to understand cancer immortality using a wide spectrum of human cancer tissues and genome editing technology.
2016 - 2016
2016 - 2016
Team project developing fundraising strategy for a Phase II biopharmaceutical startup company.